Treace Medical Concepts (TMCI) Cash from Financing Activities (2020 - 2026)
Treace Medical Concepts' (TMCI) quarterly Cash from Financing Activities came in at -$588000.0 in Q1 2026, down 108.51% YoY from $6.9 million in Q1 2025, and down 142.55% on a QoQ basis from $1.4 million in Q4 2025.
Treace Medical Concepts (TMCI) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Treace Medical Concepts (TMCI) has 7 years of Cash from Financing Activities data on file, last reported at -$588000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 108.51% year-over-year to -$588000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 2711.11% YoY) and the FY2025 annual result came in at $2.1 million, up 1198.12% from the prior year.
- Cash from Financing Activities fell to -$588000.0 in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $107.9 million in Q1 2023 to a low of -$588000.0 in Q1 2026.
- A 5-year average of $7.8 million and a median of $297000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 7762.9% — and 2025, when it plunged 225.0%.
- Tracing TMCI's Cash from Financing Activities over 5 years: stood at $297000.0 in 2022, then sank by 44.44% to $165000.0 in 2023, then plunged by 84.24% to $26000.0 in 2024, then surged by 5215.38% to $1.4 million in 2025, then slumped by 142.55% to -$588000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$588000.0 (Q1 2026), $1.4 million (Q4 2025), and -$10000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Treace Medical Concepts | 283.62 Mn | 238.00 Mn | 35.61 Mn | 696,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 696,000.00 |
| Jun 30, 2026 | 696,000.00 |
| Mar 31, 2026 | -588,000.00 |
| Mar 31, 2026 | -588,000.00 |
| Dec 31, 2025 | 1.38 Mn |
| Dec 31, 2025 | 1.38 Mn |
| Sep 30, 2025 | -10,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | 987,000.00 |
| Jun 30, 2025 | 987,000.00 |
| Mar 31, 2025 | -282,000.00 |
| Mar 31, 2025 | -282,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 311,000.00 |
| Jun 30, 2024 | 311,000.00 |
| Mar 31, 2024 | -185,000.00 |
| Mar 31, 2024 | -185,000.00 |